Posted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new medicine.
PHARMAC is pleased to announce the approval of an agreement with MSD for the funding of pembrolizumab (Keytruda) from 1 September 2016.
Pembrolizumab will be fully funded, with Special Authority, in DHB hospitals for the treatment of patients with unresectable or metastatic (advanced) melanoma, subject to the same clinical criteria as nivolumab.
